Well Lead(SH:603309)2019-04-16 16:00Financial Performance - Total revenue for Q1 2019 reached RMB 193,041,644.04, an increase of 48.68% compared to RMB 129,837,021.06 in the same period last year[7] - Net profit attributable to shareholders was RMB 19,684,019.87, representing a significant increase of 219.49% from RMB 6,161,057.74 year-on-year[7] - The net profit excluding non-recurring gains and losses was RMB 16,145,934.57, up 311.94% from RMB 3,919,506.54 in the previous year[7] - Basic and diluted earnings per share were both RMB 0.10, reflecting a growth of 233.33% compared to RMB 0.03 in the same quarter last year[7] - Net profit for the current period was ¥17,849,294.79, reflecting a significant increase of 319.49% year-over-year[14] - The company reported a total profit of ¥22,507,334.65, which is a 222.98% increase from the previous year[14] - The company reported a total profit of CNY 35,903,849.04 for Q1 2019, compared to CNY 10,053,491.36 in Q1 2018, marking an increase of 257.5%[35] Assets and Liabilities - Total assets at the end of the reporting period were RMB 1,390,496,064.75, a decrease of 1.70% from RMB 1,414,479,565.59 at the end of the previous year[7] - Total liabilities decreased to CNY 432,079,683.69 from CNY 474,412,479.32, a decline of approximately 8.9%[26] - Total equity increased to CNY 958,416,381.06 from CNY 940,067,086.27, showing a growth of about 1.9%[26] - Long-term borrowings as of March 31, 2019, were CNY 189,000,000.00, down from CNY 201,000,000.00, a decrease of approximately 6.0%[29] Cash Flow - The net cash flow from operating activities was RMB 10,870,452.75, a significant recovery from a negative RMB 13,223,806.22 in the same period last year[7] - Cash inflow from investment activities totaled CNY 88,201,958.24, compared to CNY 180,946,693.02 in Q1 2018, indicating a decrease of about 51.2%[43] - Net cash flow from investment activities was CNY 22,659,158.24, a significant recovery from -CNY 17,951,602.91 in the previous year[43] - Cash received from sales of goods and services in Q1 2019 was CNY 226,858,701.39, an increase of 16.2% from CNY 195,285,108.90 in Q1 2018[37] - Operating cash inflow for Q1 2019 was CNY 159,814,100.45, an increase from CNY 128,278,750.92 in Q1 2018, representing a growth of approximately 24.6%[42] Expenses - Research and development expenses rose to ¥4,034,253.24, marking a 98.75% increase compared to the previous year[14] - Sales expenses increased by 96.74% to ¥23,434,462.75, primarily due to the consolidation of Wolf and Medical[14] - Financial expenses for Q1 2019 totaled CNY 4,426,121.27, compared to CNY 1,611,943.38 in Q1 2018, showing an increase of 174.5%[34] - Research and development expenses for Q1 2019 were CNY 1,679,129.90, slightly up from CNY 1,610,906.69 in Q1 2018, indicating a focus on innovation[34] Shareholder Information - The total number of shareholders at the end of the reporting period was 16,930[11] - The company has not yet submitted the application for the non-public issuance of A-shares to the China Securities Regulatory Commission[19] Other Information - The addition of the consolidated subsidiary, Wolf and Medical, contributed 18.22% to the revenue growth[15] - The company plans to acquire 100% equity of Jiangxi Wolf and Medical for a total price of ¥430,000,000[18] - The company received government subsidies amounting to RMB 3,514,919.90, which are closely related to its normal business operations[7] - Cash and cash equivalents as of March 31, 2019, were CNY 80,256,793.66, compared to CNY 65,720,875.33 at the end of 2018, reflecting a growth of approximately 21.9%[27] - Accounts receivable decreased to CNY 53,067,695.39 from CNY 78,304,699.65, a reduction of about 32.2%[27] - Inventory as of March 31, 2019, was CNY 92,927,530.60, compared to CNY 85,575,869.91 at the end of 2018, indicating an increase of about 8.5%[27] - The company reported a significant increase in retained earnings, rising to CNY 391,666,976.63 from CNY 371,982,956.76, an increase of approximately 5.3%[26]